FDA Orders 23andMe to Stop Sale of Personal Genome Service

Staff - Print  | 

The U.S. Food and Drug Administration issued a warning letter to 23andMe to stop marketing and selling the company's Saliva Collection Kit and Personal Genome Service, saying the PGS had not received approval from the FDA.

The PGS is classified as a medical device because it is intended to inform users if they are at risk for a certain disease and can potentially be used as a diagnosis tool, according to the letter. Being classified as a medical device subjects the product to FDA approval before being sold to consumers.

The letter identifies false positives and false negatives from the PGS as potentially harmful for consumers, leading to a risk of patients inappropriately self-managing their healthcare.

While 23andMe submitted a 510(k)s for the PGS, the letter says the company failed to submit follow-up documents requested by the FDA, rendering the 510(k)s withdrawn.

More Articles on the FDA:

OrthAlign Receives 510(k) FDA Clearance for ORTHALIGN PLUS System

Health IT Stakeholders Weigh In on FDA Oversight

FDA Approves Alternative Epilepsy Treatment

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.